Objective To determine whether human papillomavirus (HPV) immunisation has affected the prevalence of HPV genotypes and colposcopic features of cervical intraepithelial neoplasia (CIN) in young women referred for colposcopy.
Introduction
Human papillomavirus (HPV) immunisation has been a major advance in the prevention of cervical disease and cancer. In September 2008, the bivalent vaccine (which protects against HPV 16 and 18) was introduced in the UK as part of the school-based immunisation programme. 1 The vaccine is given to girls aged 12-13 years, and the current uptake rate in schools in Scotland is 90%. 2 When the vaccine was introduced, it was also offered to girls aged 14-17 years as part of a catch-up campaign: 65.5% of the eligible catch-up group in Scotland received the full three doses. 2 Within the school vaccination programme the bivalent vaccine was used initially (2008-10), but since 2011 it was changed to the quadrivalent vaccine.
Although prophylactic HPV vaccines offer primary protection against the highest-risk HPV types, as well as a level of cross-protection for other high-risk HPV types (HPV 31, 33, and 45), 3 there will still be a residual risk of disease conferred by other high-risk HPV genotypes that are not covered by the currently licensed vaccine(s). Therefore, there is a continued need for secondary prevention using cervical screening and colposcopy.
In Scotland, cervical screening using liquid-based cytology is offered to all women aged 20-60 years, with referral to colposcopy for further investigation if the cytology shows high-grade dyskaryosis or repeated low-grade dyskaryosis or borderline nuclear abnormalities (BNAs). 4 ,5 HPV triage is not part of the screening programme in Scotland.
There is inconsistent evidence as to whether the appearance of the cervix during colposcopy is influenced by the HPV genotypes present. [6] [7] [8] [9] A study by Jeronimo et al. found that colposcopic features characteristic of high-grade cervical intraepithelial neoplasia (CIN) imply infection with HPV 16, but not necessarily other HPV types. 6 It has also been shown that lesions missed during colposcopy are more likely to test negative than to test positive for HPV 16. 7,8 In contrast, van der Marel et al. showed that the visual appearance of high-grade HPV 16 lesions at colposcopy does not differ from lesions associated with other high-risk HPV genotypes; 9 however, these studies do not include women who had been vaccinated against HPV infection. If the appearance of the cervix is associated with the HPV genotypes present, it would be anticipated that HPV vaccination might alter the range of features seen at colposcopy and thereby potentially affect the performance of colposcopy.
In this study, we investigated cervical abnormalities, HPV genotypes, and performance of conventional colposcopic evaluation in both vaccinated and unvaccinated women aged 20-25 years attending colposcopy.
Methods

Study design and population
This two-centre cross-sectional study was conducted with women aged 20-25 years routinely attending colposcopy clinics following an abnormal cervical cytology result in two Scottish teaching hospitals (Aberdeen Royal Infirmary and Edinburgh Royal Infirmary), serving regional populations. The first group (group 1) of women was recruited between February 2010 and March 2011 (before women vaccinated as part of the catch-up immunisation campaign had entered the cervical screening programme), and the second group (group 2) of women was recruited from December 2012 to November 2014 (after women vaccinated as part of the catch-up campaign had entered the screening programme). Some individuals (2008-2010) will have received Gardasil, through private arrangement, outside of the catch-up programme.
Recruitment and consent
Women were eligible if they attended colposcopy for the first time following an abnormal cytology result at routine cervical screening. Women were excluded if they were unable to understand the patient information leaflet (PIL), if they were pregnant at the time of colposcopy, or if they were being referred as a consequence of symptoms. Eligible women were sent an invitation letter and information before attending for colposcopy. At their appointment, written consent was obtained if they wished to take part in the study.
Data collection
Participants were assigned a unique study number, and data were collected on age, referral cytology, parity, and vaccination status (including vaccine type, number of doses, and age at last dose). Women were considered to be vaccinated if they received two or more doses of an HPV vaccine. 10 Information on vaccine status was obtained from the Scottish Cervical Call Recall System (SCCRS). SCCRS is the national cervical screening database that contains cytology results, associated histopathology, recall, and management data, and also immunisation status.
Colposcopy
Colposcopy was performed by BSCCP-accredited colposcopists, who recorded their findings using standard reporting features. Colposcopists were blind to the HPV status of the patient. Samples for HPV genotyping were obtained using a broom sampler before the application of acetic acid, and were stored in ThinPrep â PreservCyt â (©Hologic UK, Crawley, West Sussex, UK). Biopsies were taken if features indicative of CIN were seen at colposcopy, including acetowhite changes and capillary vessel patterns. A 'see and treat' approach was considered for women referred with high-grade dyskaryosis, in accordance with local protocols. If a punch biopsy or diathermy loop excision treatment was undertaken, these had a histological diagnosis within the local NHS pathology laboratory. Histology results were captured from pathology records.
HPV genotyping
Samples were tested at the Scottish HPV Reference Laboratory, Edinburgh, for the presence of 37 HPV genotypes using QIAamp â Media MDx, 11 followed by the LINEAR ARRAY HPV Genotyping Test (Roche Molecular Systems, Pleasanton, CA, USA). 12 High-risk HPV types were considered to be: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. Intermediate-risk HPV types were: 26, 53, 64, 66, 67, 69, 70, 73, 82, IS39, and CP6108. All other HPV genotypes that were identified were considered to be low risk.
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A subset of samples (n = 319; 88%), based on the availability of samples, were also tested for mRNA expression using PreTect HPV-Proofer (Norchip AS, Klokkarstua, Norway), which detects E6/E7 mRNA from HPV 16, 18, 31, 33, and 45. 14 
Statistical analysis
All statistical analyses were performed using SPSS 20 (SPSS Statistics for Windows, IBM, Armonk, NY, USA) Chisquare analysis was used to test for associations between vaccine status and colposcopic features, colposcopic opinion, histology results, and HPV genotypes. All P values were two sided, and for the chi-square analysis P values were considered significant if their value was <0.05. z-tests of two proportions were used to assess the difference in prevalence for each of the 35 types genotyped. As multiple statistical tests were conducted, the significance threshold for the z-tests was subject to Bonferroni correction, and therefore considered significant if their value was <0.00143 (=0.05/35).
Performance analysis of colposcopy was conducted using histology results as the gold standard for final diagnosis. In cases where no biopsy was indicated, women were assumed to have no significant disease. Sensitivity, specificity, PPV, and NPV of colposcopy were calculated for the detection of high-grade disease (CIN2+): a positive test was considered to be a colposcopic opinion of 'high grade'. Comparisons were made between vaccinated and unvaccinated women, and also between those who tested positive and those who tested negative for HPV 16. Differences in the performance of colposcopy between groups were assessed using z-tests.
Statistical power
Power analysis was conducted to calculate how many participants were necessary to reach adequate sample size using EPISTAT. The proportion of high-risk types was estimated from previously published research.
13 A 1:1 ratio for HPV 16/18 against all other HPV types was used. It was estimated that 400 women would give 95% power to detect a reduction in PPV of colposcopy from 70 to 52.5% between 200 women testing positive for HPV 16/18 and 200 women testing negative for HPV 16/18. If only 200 women in total were recruited (100 with and 100 without HPV 16/18), there would be an 86% power to detect a 30% reduction from 70 to 40%.
Results
Recruitment
A flow diagram of recruitment and study processes is included presented in Figure S1 . In group 1 (recruited before women eligible for the HPV vaccine in the catch-up campaign entered the cervical screening programme), 208 women agreed to participate and ten were excluded because they did not have a sample taken for HPV testing. Of the 198 women included in the final analysis, 172 had both HPV mRNA and DNA tests. In group 2 (recruited after women eligible for the HPV vaccine in the catch-up campaign entered the cervical screening programme), 175 women agreed to take part and 12 were excluded because they did not have a sample for HPV testing or colposcopy data. Of the 163 included in the analysis, 147 had both HPV mRNA and DNA tests. Table S1 shows the participant characteristics for each group. Vaccine status was self-reported in group 1 [three women (2%) reported being vaccinated: two received the quadrivalent vaccine and one received the bivalent vaccine]. As this could not be verified by SCCRS at the time, all women were considered to be unvaccinated. In group 2 the vaccine status was verified by SCCRS and 67 (41%) women were vaccinated. The mean age at colposcopy in both groups was 22 years. For women who had been vaccinated, the mean age at last dose was 17.3 years (SD 1.2 years) ( Table 1) .
Participant demographics
Impact of vaccination on colposcopic features and histology
As shown in Table 2 , the proportions of women with acetowhite changes (79 versus 77%), mosaic (44 versus 43%), punctation (38 versus 39%), or atypical vessels (1 versus 1%) were similar in both unvaccinated and vaccinated groups, respectively. There was no significant impact on non-iodine staining epithelium, which is noted in a higher proportion of vaccinated women (56%) compared with unvaccinated women (50%; P = 0.44). The use of iodine was inconsistent between colposcopists, and was not applied in 100 cases, thereby limiting any conclusions. Colposcopists were significantly more likely to record their opinion as high grade in unvaccinated women (34%) compared with vaccinated women (20%; P = 0.027), a difference of 14% (95% CI 2-26%). Unvaccinated women were also more likely to have high-grade disease (CIN2+): 36% compared with 19% in vaccinated women (P = 0.006), a difference of 17% (95% CI 5-29%). Unvaccinated women were also more likely to have any grade of CIN (CIN1+): 63% compared with 46% in vaccinated women (P = 0.044), a difference of 17% (95% CI 2-30%).
All eight cases of invasive squamous carcinoma or cervical glandular intraepithelial neoplasia (CGIN) were identified in unvaccinated women. All three cases of CIN3 identified in vaccinated women tested negative for HPV 16 and 18 on cervical samples: two of these were associated with HPV 33 (mRNA and DNA positive) and one with HPV 52 (DNA positive). A higher proportion of vaccinated women (40%, compared with 28% in unvaccinated women) did not have a biopsy taken (i.e. the colposcopic appearance did not indicate any significant disease). Figure 1 demonstrates the HPV genotypes that were present in vaccinated and unvaccinated women. Only six vaccinated women (9%) had HPV 16, a significantly lower proportion than was found in the unvaccinated group (47%; P < 0.001). Two (3%) of the vaccinated women had an HPV 18 infection, compared with 17% of the unvaccinated women (P = 0.003). High-risk HPV types 52, 56, and 58 were found to be present in a higher proportion of women in the vaccinated group than in the unvaccinated group (23 versus 13%, P = 0.039; 16 versus 6%, P = 0.023; and 13 versus 6%, P = 0.029, respectively). The changes in HPV 18, 52, 56, and 58 are not considered statistically significant when multiple statistical testing is accounted for. For all other high-risk HPV types, there was no difference in prevalence between vaccinated and unvaccinated women.
HPV genotyping results
A total of 319 samples were tested for HPV mRNA (HPV 16, 18, 31, 33, or 45): 172 in group 1 and 147 in Comparison of participant demographics between groups. 'Vaccinated' women refer to women who had received two or more doses of the HPV vaccination. *Group 1 includes three women who reported that they had received the HPV vaccine. **All cases where biopsy was not taken were because colposcopic appearances were normal. group 2. Although 14 (25%) samples in the vaccinated group had a transcriptionally active HPV infection indicated by the mRNA results, there was a significantly higher proportion of women in the unvaccinated group (63%) with transcriptionally active HPV infections (P < 0.001).
Of the vaccinated group, four (7%) tested positive for HPV 16 mRNA compared with 101 (38%) of the unvaccinated group (P < 0.001).
Impact of HPV 16 infection on colposcopic features and histology
There was no association between the presence of HPV 16 DNA or HPV 16 mRNA and any individual colposcopic features. Despite this, colposcopists were more likely to record a colposcopic opinion of high grade if participants tested positive for HPV 16 DNA (57%; P = 0.006) or HPV 16 mRNA (59%; P = 0.03), than if the woman tested negative for HPV16 DNA/mRNA (37 and 43%, respectively). Women were also more likely to have a high-grade histology result if they tested positive for HPV 16 DNA (71%; P < 0.001) or HPV 16 mRNA (77%; P < 0.001), than if they tested negative (38 and 43%, respectively). 
Performance of colposcopy
Discussion
Main findings
Vaccination in the catch-up cohort is associated with a significant reduction in the prevalence of HPV 16/18 and CIN2+ in women aged 20-25 years attending colposcopy in Scotland. 3 Our results show that colposcopic features were similar in vaccinated and unvaccinated women, and that differences were related to the incidence of cervical disease. Our results indicate that the performance of colposcopy in vaccinated women has not diminished substantially; however, the PPV for CIN2+ was lower in vaccinated women (albeit not at a statistically significant level).
Strengths and limitations
To our knowledge, this study is the first to investigate the impact of HPV genotypes on colposcopic features associated with CIN in women immunised for HPV. This is possible as cervical screening in Scotland starts earlier than in many countries, with vaccinated women entering our national programme in 2010. Scotland achieved high rates of vaccination in the catch-up campaign (65.5%), and has a reasonable 3-yearly cervical screening uptake (70.7% overall, 50.9% in 20-24 year olds). 15 For group 2 we were able to assign vaccine status using SCCRS to improve the reliability.
To minimise bias, colposcopists and histopathologists were blinded to HPV results, and staff undertaking the HPV genotyping tests were blinded to vaccine status.
As the aim of the immunisation is to reduce deaths from cervical cancer, it could be that we have to wait at least 30 years before this can be measured confidently. The long lead time between HPV infection and the development of malignancy means that high-grade CIN (as used in our study) is a justifiable surrogate marker for cervical cancer. 16 Where the cervix appeared normal, biopsies were not taken (in accordance with local protocols), so these women lacked a 'gold-standard diagnosis' and were classified as 'disease negative' for analysis. A high proportion of women who did not have a biopsy taken were subsequently found to test negative for HPV 16. This resulted in a high NPV of colposcopy for detecting high-grade disease in women testing negative for HPV 16, despite there being no histological confirmation of disease status for them. The NPV of colposcopy has previously been recorded as high (up to 96%), so we expect to miss very few cases of CIN. 17, 18 As Jeronimo et al. 6 suggested that high-grade CIN is more likely to be missed by colposcopy in the absence of HPV 16, it may be that the women testing negative for HPV 16 with normal colposcopy have disease that lacks characteristic colposcopic features. Follow-up of our cohort in the future will address this.
Interpretation
We believe that this is the first study conducted with this primary aim in women who have received HPV vaccine. [6] [7] [8] [9] Previous studies reporting on the impact of HPV genotypes on colposcopy were conducted as ad hoc analyses of larger studies with inconsistent results. Jeronimo et al. found that HPV 16 was more likely to produce lesions with colposcopically identifiable features than other HPV types, regardless of histology. 6 Louwers et al. 7 reported that the presence of HPV 16 significantly improved the sensitivity of the dynamic spectral imaging colposcopy for CIN, and hypothesised that HPV 16 is associated with acetowhitening. Using data from this same study, Zaal et al. 8 found that HPV 16 did not impact the performance of standard colposcopy, and suggested that effects were dependent on the underlying grade of disease, rather than HPV 16 in itself. Similarly, van der Marel found that the visual appearance of high-grade HPV 16 lesions did not differ from lesions associated with other high-risk HPV types.
9
Our results support this with no significant difference in relation to either vaccine status or presence of HPV 16. Changes in PPV relate to the reduced incidence of highgrade disease in immunised women, as PPV is strongly influenced by disease prevalence and the reduction reflects the reduction in CIN. 19 With the emerging cohort of women who received HPV immunisation as part of routine vaccination, rather than through the catch-up programme, it is important to clarify the effect of reducing or even eliminating HPV vaccine types from the screened population, as we use colposcopy to identify and treat CIN.
We did not find any association between HPV 16 and acetowhitening in women attending colposcopy. Colposcopists were able to identify HPV 16-negative lesions during colposcopy, which were confirmed on biopsy. The women included in our study were younger (mean age 22.3 years) compared with previous studies (mean age ranged from 26.2 to 36.7 years). [6] [7] [8] [9] Given that the peak prevalence of HPV infection occurs in women before that of CIN, we anticipate that the impact of HPV genotypes on colposcopic features may also vary according to age. 20 The vaccinated women in this study received the HPV immunisation as part of the catch-up campaign. The mean age at last dose was 17.3 years. Women were not asked about sexual activity. It is likely that some of these women were sexually active and therefore not HPV na€ ıve prior to vaccination. 3, 21, 22 Our study suggests that, compared with unvaccinated women, lower proportions of vaccinated women had highgrade cervical cytology. A similar observation has been made in Australia. 16 This study reported a significant decrease (38%; P = 0.003) in high-grade cervical abnormalities in young girls (under 18 years of age) following the introduction of the HPV vaccine, but no significant decrease in the incidence of low-grade cervical abnormalities in this age category, or in women aged 18-20 years. As the cohort vaccinated in the school programme at age 12 years enters screening in 2021 in the UK, we would expect to see a greater impact on PPV, with lower disease rates, if we do not review the risk stratification of our screening policy.
Our results are consistent with those reported in the screened population in Scotland with a significant reduction in circulating HPV vaccine types and associated disease, and provides further evidence of the success of the vaccination programme. 3, 20, 23 The prevalence of HPV 16/18 in vaccinated women attending colposcopy is similar to that in young women attending cervical screening (11.5% at colposcopy, compared with 11.0% and 13.6% at screening).
3,23 Kavanagh et al. found that HPV 51 and 56 were the most prevalent HPV genotypes in vaccinated women attending cervical screening (10.5 and 9.6%, respectively). 3 The prevalence of HPV 51 and 56 was higher in the vaccinated women attending colposcopy compared with the unvaccinated women (15.7% for each, compared with 12.7 and 5.8%, respectively, in unvaccinated women) in our study. In contrast to Kavanagh et al., we found that HPV 52 and 59 emerged as the most prevalent HPV genotypes in vaccinated women attending colposcopy with abnormal cytology (22.9 and 17.1%, respectively). Different HPV assays were used in those studies, however, which may influence HPV genotype detection.
Conclusion
We found no significant impact of vaccination on colposcopic features in women aged 20-25 years with abnormal cervical cytology who had received the HPV 16/18 vaccine as part of a catch-up campaign. Despite the lower prevalence of HPV 16 in vaccinated women, features considered characteristic of high-grade CIN were still detectable. Cervical screening needs to continue to offer protection from disease from non-vaccine types; however, the reduction in prevalence of CIN has impacted on the PPV of colposcopy, and this has implications for quality assurance of colposcopy in the cervical screening programme.
In order to assess the impact of the HPV vaccination on colposcopy performance further, studies should be conducted when the women who received the vaccine as part of the school-based immunisation programme (in whom the coverage rates were 90%) enter the cervical screening programme.
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